Inhibrx Biosciences, Inc. (INBX)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Biologic Therapeutics	1.80M
Biologic Therapeutics Growth	-17.88%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
United States	1.80M
United States Growth	-17.88%